Horizon Bancorp Inc. IN Has $781,000 Stake in Abbott Laboratories $ABT

Key Points

• Horizon Bancorp Inc. increased its stake in Abbott Laboratories by 58.1%, owning a total of 5,739 shares valued at approximately $781,000 as of the end of Q2.
• Abbott Laboratories reported a quarterly earnings per share (EPS) of $1.26, meeting analyst expectations, and a revenue of $11.14 billion, which surpassed predictions.
• The company declared a quarterly dividend of $0.59, with a yield of 1.8%, to be paid on November 17th, 2025, alongside setting FY 2025 EPS guidance at 5.100-5.200.

Horizon Bancorp Inc. IN boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 58.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,739 shares of the healthcare product maker's stock after buying an additional 2,110 shares during the quarter. Horizon Bancorp Inc. IN's holdings in Abbott Laboratories were worth $781,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ABT. Hughes Financial Services LLC acquired a new position in Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC bought a new stake in Abbott Laboratories during the first quarter valued at about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the first quarter valued at about $30,000. JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC bought a new stake in Abbott Laboratories during the first quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $133.24 on Friday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $231.90 billion, a PE ratio of 16.70, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69. The firm has a 50-day moving average price of $132.44 and a 200 day moving average price of $131.52.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the business posted $1.14 earnings per share. The company's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ABT shares. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Morgan Stanley upped their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Wells Fargo & Company reduced their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Finally, BTIG Research reduced their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $146.24.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.